Clinical trials: Esophagogastric Junction Cancer
Adenocarcinoma of the Esophagogastric Junction
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Metabolic and Molecular Response evaluation for the individualization of therapy in adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for patients with metabolically (ie, according to PET…
- Trial name
- MEMORI (NCT02287129)
- Testing
- Oxaliplatin, Epirubicin, Capecitabine
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Technical University of Munich
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy…
- Trial name
- NCT05671822
- Testing
- SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in…
- Trial name
- MONEO (NCT03979131)
- Testing
- Avelumab addition to perioperative chemotherapy in GC and GEJC
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Advanced Solid Tumors, Gastric Cancer
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer
- Trial name
- NCT05275062
- Testing
- IM92 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Gastric Cancer
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction…
- Trial name
- NCT06374901
- Testing
- Tislelizumab, SOX/XELOX
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Xiangdong Cheng
Gastric Cancer, Hepatocellular Carcinoma
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on…
- Trial name
- NCT04798781
- Testing
- Telatinib, Keytruda
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Andrew Hendifar, MD
Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice
This study uses existing cancer registry and health record data to understand how nivolumab is used in routine care in the Netherlands for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach.
- Conditions
- Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07663786
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 726 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Cancer, Gastroesophageal Junction Cancer
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.
The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer…
- Conditions
- Esophageal Cancer, Gastroesophageal Junction Cancer, Anastomotic Leak
- Trial name
- PLACE020 (NCT03529266)
- Testing
- Porcine Fibrin Sealant (PFS), Surgery
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer
Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with…
- Conditions
- Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
- Trial name
- NCT07855757
- Testing
- Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Gastroesophageal Junction Cancer
STRENGTH Expansion
Patients seen in the EGMDC (Esophageal and Gastric Multidisciplinary Clinic) for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro will be offered enrollment into the study.
- Trial name
- NCT04520867
- Testing
- STRENGTH
- Where
- United States
- Sponsor
- University of Colorado, Denver
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Esophageal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00711412
- Testing
- Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Gastric Adenocarcinoma
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy has been recommended by a series of treatment guidelines for the neoadjuvant treatment of locally advanced G/GEJ cancer.
- Trial name
- NCT06667050
- Testing
- Chemotherapy plus sintilimab and bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- West China Hospital
Gastric Cancer, Esophagogastric Junction Disorder
Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer
Gastrectomy is the main treatment for gastric and Siewert type II-III esophagogastric junction (EGJ) cancer. This surgery is associated with significant morbidity.
- Trial name
- NCT03909997
- Where
- Chile
- Volunteers
- 300 people
- Sponsor
- Hospital Dr Sotero del Rio
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
TAC T-cells for the Treatment of HER2-positive Solid Tumors
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
- Trial name
- TACTIC-2 (NCT04727151)
- Testing
- TAC01-HER2, TAC01-HER2 plus pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Triumvira Immunologics, Inc.
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer, Gastroesophageal-junction Cancer
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to find out whether adding cadonilimab to the usual chemotherapy approach is an effective and safe treatment for participants with locally advanced/resectable gastric cancer or gastroesophageal…
- Trial name
- NCT07631000
- Testing
- Cadonilimab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stomach Neoplasms, Neoplasms Metastasis
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease are to be recruited in the study.
- Conditions
- Stomach Neoplasms, Neoplasms Metastasis, ERBB2 Gene Amplification
- Trial name
- NCT02004769
- Testing
- Trastuzumab, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sun Yat-sen University